期刊
LEUKEMIA RESEARCH
卷 71, 期 -, 页码 60-62出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2018.07.010
关键词
Myelodysplastic syndromes; MDS; Multilineage dysplasia; Ring sideroblasts; ASXL1; Bone marrow morphology; Prognosis; MDS-RS; MDS-MLD; RCMD
资金
- Gerstner Family Career Development Award
- Mayo Clinic Center for Individualized Medicine
- CTSA Grant from National Center for Advancing Translational Science [KL2 TR000136]
Introduction: The 2016 World Health Organization (WHO) classification of myeloid neoplasms reclassified patients with myelodysplastic syndromes (MDS) with multilineage dysplasia (MLD) based on the presence or absence of ring sideroblasts (RS). We performed this study to validate this change in the context of relevant gene mutations. Methods: WHO-defined MDS and MLD were identified with detailed clinical, cytogenetic and outcomes data. A 32-gene targeted exome sequencing panel was performed on bone marrow samples obtained at diagnosis. Results: Ninety eight patients were included; 59 (60%) MDS-MLD and 39 (40%) MDS-RS-MLD. There were no significant differences in the median overall survival (OS) in the two groups (25 months each, p = 0.6). Among the myeloid-relevant gene mutations, presence of ASXL1 (HR 2.5, p = 0.005) was identified as an adverse prognostic factor in a multivariate analysis. Conclusion: While segregation of MDS-MLD based on RS holds little prognostic relevance, ASXL1 mutational status significantly and independently predicts poor outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据